



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395, C07K 14/00, C12N 15/70, 15/79		A1	(11) International Publication Number: WO 95/04548
			(43) International Publication Date: 16 February 1995 (16.02.95)
(21) International Application Number: PCT/US94/09045		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FL, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, PT, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).	
(22) International Filing Date: 10 August 1994 (10.08.94)			
(30) Priority Data: 08/105,444 11 August 1993 (11.08.93) US			
(71) Applicant: JENNER TECHNOLOGIES [US/US]; 1895 Mountain View Drive, Tiburon, CA 94920 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors: SPITLER, Lynn, E.; 1895 Mountain View Drive, Tiburon, CA 94920 (US). MAIDA, Anthony, E., III; 828 Eastbrook Court, Danville, CA 94506 (US).			
(74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006 (US).			

(54) Title: PROSTATIC CANCER VACCINE

(57) Abstract

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of: at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating *in situ* said antigen or portion; a naked DNA encoding said antigen or portion; and an antiidiotypic antibody or fragment thereof which mimics said antigen or portion.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PROSTATIC CANCER VACCINE

Technical Field

The present invention is related to the field of the prevention and treatment of prostate cancer. More specifically, the invention concerns the use of (1) prostate associated antigen(s), (2) expression systems for prostate associated antigen(s) which are peptides or proteins or (3) antiidiotypic antibodies bearing the internal image of the antigen(s) formulated as vaccines to produce an immune response to prevent or treat prostate cancer.

Background Art

Cancer is the second leading cause of death in the United States accounting for almost 500,000 deaths each year. More than 1,000,000 new cases of cancer are diagnosed in the United States annually. The incidence of cancer is increasing largely as a byproduct of the greater lifespan of the aging population. Cancer is a leading cause of death in all industrialized nations, where life expectancy continues to increase. It is expected that cancer morbidity and mortality will continue to increase in all industrialized areas of the world.

Prostate cancer is the most common malignancy among males in the U.S. accounting for 28% of all malignancies in men. It is estimated there will be 165,000 new cases of prostate cancer in the United States in 1993 and 35,000 deaths (Boring, CC, et al CA Cancer J Clin (1993) 43:7-26).

Prostate cancer continues to be refractory to treatment despite many years of efforts to improve therapy. Surgery and radiation remain the mainstays of therapy; improved therapeutic modalities are needed. Vaccine development has been slow and no vaccine approved by the FDA for marketing currently exists for any form of cancer. There is therefore a continuing need for the development of new therapeutic and prophylactic compounds effective in the prevention and treatment of prostate cancer.

- 2 -

The use of vaccines as cancer therapy is known (reviewed in Hoover, Jr. HC and Hanna, Jr. MG, Biological Therapy of Cancer (1991) Devita, Jr., DT, et al., eds. J.B. Lippincott Co., pp 670-701. There are many reports in the open
5 literature of vaccines consisting of whole autologous or allogeneic tumor cells or their extracts formulated with bacterial adjuvants such as Bacillus-Calmette-Guerrin (BCG), *Corynebacterium parvum* or vaccinia virus. There has been no report of the use of an antigen unique to the prostate such as a
10 prostate associated protein or an antiidiotypic antibody bearing the internal image of the prostate antigen as a vaccine for prostate cancer.

U.S. Patent No. 3,960,827 describes a cancer-associated polypeptide antigen which is described as having a
15 molecular weight of 20-27 kd and as associated with a number of types of cancers. The use of this antigen in antitumor vaccines is suggested. U.S. Patent No. 4,372,945 discloses the use of tumor cells as secondary antigens in immunotherapeutic treatment of cancer. U.S. Patent No. 4,446,122 discloses the use of
20 prostate specific antigen (PSA) isolated from human tissue to prepare antibodies for tumor diagnosis. U.S. Patent No. 4,468,457 describes the isolation of a colon specific antigen which is digested with trypsin to obtain a peptide used to produce monospecific antibodies against the antigen. U.S.
25 Patent No. 4,689,222 describes a method for alleviation of symptomatic pain associated with neoplasia by administering a low dose of human chorionic gonadotropin insufficient to provoke a humoral response. U.S. Patent No. 4,877,611 describes vaccines containing tumor-associated antigens. The vaccines
30 contain the tumor-associated antigen in the presence of specific adjuvants. PCT application WO91/11465 describes anticancer vaccines using antiidiotype antibodies that mimic an antigen produced by or associated with the malignant cell.

U.S. Patent No. 5,053,224 issued October 1, 1991
35 describes the preparation of both polyclonal and monoclonal antiidiotypic antibodies that recognize the paratope of an antitumor antibody. The issued patent further describes the use

of these antiidiotypic antibodies generally to stimulate the production of anti antiidiotypic antibodies in tumor patients. Copending patent application No. 07/938,079 filed 8/31/92, the disclosure of which is incorporated herein by reference

5 discloses the use of antiidiotypic antibodies generally to stimulate an antitumor T cell response for prevention and/or therapy of cancer. Copending patent application No. 07/800,474 filed 11/26/91, the disclosure of which is incorporated herein by reference describes generally the use of pure tumor antigen
10 encapsulated in or conjugated to liposomes for the treatment and prevention of cancer.

The present invention concerns the use of prostate antigens or their representatives in vaccines to produce an immune response to prevent or treat prostate cancer.

15 Disclosure of the Invention

While the prior art suggests the use of antigens uniquely associated with tumor tissue as components of antitumor vaccines, there appears to be no suggestion to use antigens which are uniquely represented on host tissue for the tumor.

20 Since the prostate is not an essential organ, elimination of the prostate gland, which may be a concomitant effect of the vaccines of the invention, does not adversely impact the general health of the subject. Thus, prostate cancer offers a unique opportunity for treatment with vaccines which characterize the
25 host organ itself, rather than the malignant or metastatic nature of the cells per se.

Accordingly, in one aspect, the invention is directed to a method to induce an antitumor immune response in a potential or actual prostate tumor-bearing subject which method
30 comprises administering to said subject a composition comprising an active ingredient selected from the group consisting of at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating *in situ* said antigen; and an antiidiotypic
35 antibody or fragment thereof which mimics said antigen.

- 4 -

In another aspect, the invention is directed to a pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors which comprises, as active ingredient, at least one antigen over-represented on the prostate gland with respect to other tissues or an immunologically effective portion thereof; or an expression system capable of generating in situ said antigen; or an antiidiotypic antibody or fragment thereof which mimics said antigen.

10 Modes of Carrying out the Invention

The invention utilizes compositions which contain, as active ingredient, at least one antigen which is over-represented on prostate tissue or an immunologically effective portion thereof or a representative thereof. By "over-represented" is meant that the concentration of this antigen in prostate is sufficiently higher than its concentration in any other tissue such that the prostate can effectively be targeted by the immune response raised against this antigen with relative sparing of other organs or tissues. Sparing can be measured by overall clinical toxicity to the subject. Toxicity to the subject is generally grade 3 or less, preferably grade 2 or less most preferably grade 1 or grade 0. The approach does not lose value with regard to metastatic prostate cancer, since the antigens over-represented in the prostate gland are also carried by the metastatic cells.

By an "immunologically effective portion thereof" is meant that portion of an antigen, taken alone, which is capable of eliciting an immune response. Typically, such portions represent an individual epitope or a specific subset of the epitopes that comprise the complete antigen.

The antigen can be any substance which is, in the sense used above, unique to or over-represented in prostate tissue. Thus, the antigen may be a protein or a peptide, or peptide fragment of the protein, or may be a carbohydrate, glycoprotein, lipoprotein or lipid. Most commonly, the antigen will be a protein or a peptide fragment thereof; or a protein

which includes the amino acid sequence of the antigen or epitope. Proteins may be modified by glycosylation or other derivatization. It is clear that in the case of protein antigen, peptides representing epitopes of the antigen may also
5 be used. The relevant amino acid sequence can be supplied in the context of a larger fusion protein that contains amino acid sequence heterologous to the antigen or its epitope.

It is also understood that in the case of peptide or protein antigens, the antigens may be generated *in situ* by
10 providing suitable expression systems containing the DNA encoding the desired peptide or protein (including fusion proteins containing the relevant sequence); the expression systems can then be used as the active ingredient in the vaccines. By "expression system" is meant any DNA construct
15 which is effective in producing the encoded protein in the desired environment. Conventional expression systems contain the encoding DNA operably linked to control sequences such as promoters, terminating signals and the like. However, it has recently been shown that the coding sequences per se can behave
20 as effective expression systems *in situ* when injected into animals. The work of Ulmer, J.B., et al., Science (1993) 259:1745-1749, and summarized in a "Research News" presentation by Cohen, J., in the same issue on pages 1691-1692 demonstrates this concept. Injection of "naked" DNA encoding the
25 nucleoprotein of influenza A was shown to be protective against a challenge of the virus. Although it is not understood why such naked DNA is apparently capable of expression to provide the protein *in situ*, this apparently is the case. Accordingly, such "naked" DNA is included in the definition of expression
30 systems herein.

Furthermore, any antigen may be mimicked by an antiidiotypic antibody; it has long been recognized that antiidiotypic antibodies can be prepared that bear an internal image of tumor associated antigens, (Herlyn, D., et al. Science
35 (1986) 232:100-102.

- 6 -

Illustrative Antigens

The first widely studied antigen which is over-represented in the prostate gland is prostatic acid phosphatase (PAP). Elevated levels of PAP in the bloodstream are considered indicative of prostate cancer, and this enzyme has been widely studied (Yam, Amer J Med (1974) 56:604. Improved methods of cancer detection using this enzyme were described by Chu et al. in PCT application WO79/00475. The structure of the enzyme has also been studied by Sharief, F.S., et al., Biochem Biophys Res Commun (1992) 184:1468-1476 and by Van Etten, R.L., et al., J Biol Chem (1991) 266:9993-9999. The nucleotide sequence encoding human PAP has been determined from a full length cDNA clone (Sharief, F.S., et al., Biochem Biophys Res Commun (1989) 180:79-86; Tailor, P.G., et al., Nucleic Acids Res (1990) 18:4928.

In addition to PAP, other suitable candidates for antigens over-represented on prostate tissue are known. Most prominent among these is "prostate specific antigen" or "PSA".

U.S. Patent No. 4,446,122 discloses methods for the purification of human prostate specific antigen (PSA) from either normal or cancerous human prostate tissue, prostatic fluid, cultured human prostatic malignant cells, or their media. Also disclosed are polyclonal and monoclonal antibodies to the prostate specific antigen and their use in a method for diagnosing carcinoma of the prostate. PSA is a member of the glandular kallikrein family and is a protease with a restricted chymotrypsin-like specificity; it is present in the epithelial cells comprising the prostatic ductal elements. It has been demonstrated in all primary and metastatic prostatic tumors tested and in normal benign prostate but not in nonprostatic cancer tissues or in normal tissues other than prostate.

The complete amino acid sequence of PSA from human seminal plasma has been determined (Watt KW et al., Proc Natl Acad Sci USA (1986) 83:3166-3170). PSA consists of a single polypeptide chain with 240 amino acid residues and has a calculated molecular weight of 26,496. Carbohydrate side chains are possibly attached. The cDNA encoding PSA has been produced

and characterized (Lundwall A, Lilja, H, FEBS Lett (1987) 214:317-322; Schultz P, et al., Nucleic Acids Res (1988) 16:6226; and Henttu P and Bihko P, Biochem and Biophys Res Commun (1989) 160:903-910). The gene for the PSA has also been
5 characterized (Lundwall A, Biochem and Biophys Res Commun (1989) 162:1151-1159, Riegman, PHJ, et al., Biochem and Biophys Res Commun (1989) 159:103-111 and Klobeck G, et al., Nucleic Acids Res 1989 17:3981.)

cdNA encoding a different prostate specific membrane
10 antigen (PSMA) has also described (Israeli RS et al., Cancer Res (1993) 53:227-230). The cdNA consists of 2.65 kilobase and a portion of the coding region from nucleotide 1250 to 1700 has 54% homology to the human transferrin receptor mRNA. In
contrast to PSA and prostatic acid phosphatase which are
15 secreted proteins, the prostate specific membrane antigen is an integral membrane protein.

The PSMA (molecular weight 100,000) similarly has representation on both benign and neoplastic prostate cells with more intense staining seen with malignant cells. Metastases of
20 prostate cancer also have representation of the antigen. This antigen, therefore, is an appealing as a vaccine candidate for the same reasons as those described for PSA. Moreover, PSMA is an integral membrane protein rather a secreted protein as is PSA, and, therefore, may be an even more appropriate vaccine
25 component.

The foregoing list of known antigens which are over-represented on prostate: prostatic acid phosphatase (PAP); prostate specific antigen (PSA); and prostate specific membrane antigen (PSMA) is offered for the purpose of illustration.
30 These well known antigens (or the epitope bearing fragments thereof) are proteins (or peptides) and are useful in the vaccines of the invention. However, the invention includes any other antigens substantially uniquely present on the prostate gland so that prostate derived tissue can be distinguished from
35 other tissue by virtue of the presence of these antigens.

Preparation of the Antigens

Antigens useful in the vaccines may be prepared by any suitable methods. The antigens may be isolated and purified from prostatic tissue using conventional methods. The purification of the representative antigens set forth above is already known, and art-known techniques for their purification may be employed. In addition, affinity columns employing antibodies or fragments thereof for specific adsorption of the desired antigen can be used to advantage. The nature of the purification method will, of course, depend on the nature of the antigen obtained.

For antigens that are proteins or peptides, a number of options is available in addition to isolation and purification. In addition to genetic engineering techniques, peptides, and even proteins, can be prepared using standard chemical synthesis methods, preferably the commercially available solid-phase-based techniques. These techniques are well known and automated systems to conduct them can be purchased and employed according to the manufacturer's instructions.

In addition, protein or peptide antigens may be prepared using genetic engineering. Procedures for the production of pure antigens from the DNA encoding the desired antigen are well known to those skilled in the art. Briefly, the preferred DNA is expressed in a suitable recombinant expression vector such as those adapted for *E. coli*; yeast, such as *Saccharomyces cerevisiae* or *Pichia pastoris*; or filamentous fungi such as *Aspergillus nidulans*. The yeast, fungi or bacteria, can be grown in continuous culture producing recombinant protein which may be then be isolated and purified. Alternately, higher organisms may be used for recombinant protein production. For example, the encoding DNA may be expressed in an insect virus expression vector such as recombinant baculovirus and the resulting recombinant baculovirus then used to infect susceptible cultured SF9 cells (*Spodoptera frugiperda* insect cells) to produce the protein product of the DNA. Other expression systems commonly used

include those appropriate for production of proteins in mammalian cells, such as CHO cells or even plant cells. The choice of host will determine the nature of the posttranslational processing, and is a consideration in devising
5 purification techniques.

The preparation of recombinant forms of protein antigens in a variety of host cells results in a variety of posttranslational modifications which affect the immunogenicity and other pharmaceutical properties, such as pharmacokinetics,
10 of the product. Accordingly, although human prostate-specific antigen (PSA) isolated from human tissues has been used to induce the production of antibodies for diagnostic use, the immunogen prepared in this way differs from the immunogen as prepared in nonhuman cells, such as insect cells. The
15 posttranslational modifications peculiar to the recombinant host result in alternations in glycosylation pattern, folding, and the like.

The technique of recombinant expression may also be used to produce portions of the desired antigen rather than the
20 entire antigen. For example, it may be desirable to express the extracellular domain without the intracellular and/or transmembrane domains to facilitate purification of membrane associated antigen. Similarly, it may be desirable to express just the epitopes of choice eliminating unrelated or competing
25 epitopes. All of these may be accomplished through techniques well known to those skilled in the art. Techniques for identifying peptides representing important epitopes of the antigen are well known, and are summarized in Berzofsky, JA and Berkower IJ, Fundamental Immunology 2nd edition, Raven Press,
30 (1989) W. E. Paul (ed.) pp. 169-208. The peptides identified may then be synthesized using conventional solid phase peptide synthesis (Merrifield RB, J Am Chem Soc (1983) 85:2149-2154) which has now been automated (Merrifield RB, Science (1965) 150:178-185) as described above. An alternate method designed
35 to make large numbers of peptides for screening is the "tea-bag" technique (Houghten RA, Proc Natl Acad Sci USA (1985) 82:5131-5135.

- 10 -

Whether the antigen or a suitable epitope is prepared synthetically or recombinantly, it may be prepared initially as a fusion protein containing amino acid sequence heterologous to the amino acid sequence of interest. Construction of such fusion proteins is common in recombinant production in order to stabilize the product produced in the cell. It may be unnecessary to stabilize the desired peptide or protein in this way, especially if it is to be secreted from the recombinant cell. However, the fusion protein itself may be useful as an ingredient in the vaccine, especially if the additional heterologous amino acid sequence supplies an immunogenicity enhancing property on the relevant epitope. Thus, the fusion proteins which contain the relevant amino acid sequences may be used simply as precursors of the immunogen or may provide the end-product for use in the vaccine. If the fusion protein is intended as an intermediate, it is useful to provide a cleavage site between the heterologous portion and the desired epitope. Such cleavage sites include, for example, the target sequences for various proteolytic enzymes, or, if the epitope does not contain methionine, may constitute simply a methionine residue which is cleaved by cyanogen bromide. Methods to provide suitable cleavage sites are well known in the art.

Preparation of Antiidiotypic Antibodies

An alternative approach in formulating the vaccines of the invention is to prepare a "representative" of the antigen in the form of an antiidiotypic antibody which bears an internal image of the antigen. Antiidiotypic antibodies can be prepared with respect to antigens of any chemical nature, including, in addition to peptides and proteins, carbohydrates, lipids, and small molecules.

Ways to prepare both monoclonal and polyclonal antiidiotypic antibodies which bear the internal image of the tumor associated antigens is described in detail in U.S. Patent No. 5,053,224 the disclosure of which is incorporated herein by reference. Briefly, polyclonal antiidiotypic antibodies may be produced by immunizing animals with monoclonal idiotypic

antibodies raised against the antigen and screened for reactivity with the antigen and screening for antisera which react with idiotypic antibodies to the prostate antigens. Monoclonal antibodies may also be prepared from such animals using standard techniques of immortalizing the antibody secreting cells of the animal and screening the cultures with idiotypic antibodies in competition with the prostate antigen. Human or murine monoclonals are preferred; polyclonal preparations made in a variety of mammalian systems may also be used.

Vaccine Compositions

While the prostate antigens of the invention may by themselves constitute the vaccine, it is a further feature of the invention these prostate antigens are administered in a formulation designed to enhance the antitumor response. Formulations include but are not limited to incorporation of the prostate antigen into a liposome with or without out additional adjuvants, use of adjuvants and/or cloning DNA encoding of peptide or protein antigens into a viral or bacterial vector.

Of course, the formulations may not contain only a single active ingredient; any combination of the immunogenic substances of the invention can be used. However, generally, such "cocktails" comprise active ingredients of the same type -- i.e., generally the active ingredient mixture will include either two or several antigens, two or several expression systems for protein or peptide antigens, or two or several antiidiotypic antibodies representing different antigens. However, there is no theoretical reason that, for example, a single vaccine could not include both antiidiotypic antibody and an expression system.

If the protein form of the antigen is to be used, it may be desirable to couple the protein or peptide to a carrier in order to enhance immunogenicity. Such coupling can be effected using standard and conventional coupling techniques, optionally utilizing spacer moieties in order to provide correct juxtaposition of the carrier and epitope. A large number of

- 12 -

suitable carriers for such purposes is known, including keyhole limpet hemocyanin, rotavirus VP6 inner capsid protein, pilin protein and the like. In addition, enhanced immunogenicity may be obtained by supplying the epitope or antigen in the form of a fusion protein wherein the epitope bearing portion is fused to heterologous amino acid sequences to enhance the effect of the epitope administered.

Whether administered alone, coupled to carrier, or as part of a fusion protein, the epitope bearing proteins of the invention, the DNA constructs and the antiidiotypic antibodies are administered in the presence of suitable excipients. Conventional excipients may be used, but the following are of particular interest.

Compositions employing liposomes encapsulating or conjugating to the active ingredient of the vaccine may be used and are especially preferred. Liposomes localize in the reticuloendothelial system, one of the sites of generation of the immune response in a mammalian host including humans and enhance the immune response to antigens incorporated in the liposome. The liposomal formulations incorporating the prostate antigens may also include immune system adjuvants, including one or more of lipopolysaccharide (LPS), lipid A, or muramyl dipeptide (MDP) as described in Liposomes, Ostro MJ, Editor, Marcel Dekker, Inc. (1983) page 249). Other immune system adjuvants such as glucan or certain cytokines, including interleukins, interferons, and colony stimulating factors, such as IL1, IL2, gamma interferon, and GM-CSF may also be incorporated with antigen into the liposome.

The prostate antigen may also be formulated with various adjuvants which enhance antitumor response, in particular, cellular immune response to the prostate antigens. Such adjuvants include, but are not limited to, Freund's Complete Adjuvant, alum, lipid A, monophosphoryl lipid A, *Bacillus-Calmette-Guerrin* (BCG) and other bacteria, polysaccharides such as glucan, acemannan, and lentinan, saponins, detoxified endotoxin (DETOX), muramyl tripeptide, muramyl dipeptide and their derivatives, SAF1, lymphokines and

cytokines, including interleukins and interferons such as IL2 and gamma interferon, as well as colony stimulating factors such as GM-CSF, nonionic block copolymers, or immune stimulating complexes (ISCOMS).

5 In an additional formulation the DNA encoding proteins such as PAP, PSA, PSMA, or portions of these is administered in a viral expression vector such as vaccinia or other pox virus or bacterial vectors such as BCG. Viral vectors are described, for example, by Hruby, D E, Vet Parasitol (1988) 29:281-282, and by
10 Uiu, SI "AIDS Research Reviews" Dekker, Inc. (1991) 1:403-416. The recombinant vectors may be administered in the traditional manner via a skin scratch or an injection or may included in a liposome injectable as described above. As noted above, "naked" DNA can also be used as a form of expression system in the
15 vaccines of the invention.

Administration and Use

In the method of the invention, the prostatic cancer vaccine is administered for both prevention and treatment of prostatic cancer. The prostatic cancer vaccine of the invention
20 is administered to subjects at risk for the development for the development of prostate cancer or showing a diagnosis thereof. While the target cancer is specifically that associated with the prostate gland, the effect of the vaccines of the invention will be to enhance the potential of the immune system generally,
25 generating T cell responses as well as the production of antibodies. To the extent that the enhancement of the cellular immune system is effected, the vaccines of the invention are useful in the prevention and therapy of other types of cancer as well as that of the prostate. Thus, the cellular responses
30 generated are effective against, for example, cancers of the colon, lung, bladder, stomach, breast, cervix, and the like as well as certain lymphomas and leukemias.

The compositions are formulated for parenteral administration using a formulation appropriate to the
35 administration route such as those described in Remington's

- 14 -

Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, PA.

Suitable routes for parenteral administration include intracutaneous, subcutaneous, intramuscular, and intravenous injection or oral administration. For formulation for injection, the vaccine is generally formulated in a suitable liquid such as Hank's solution or Ringer's solution along with suitable excipients providing buffering, stabilizing, and other desirable characteristics, as well as additional components desired, as described below. Alternative routes for parenteral administration include oral administration in which case additional components for stabilizing the preparation may also be included.

In addition to administration in an appropriate isotonic vehicle for injection, liposomes are desirably used as a carrier to direct the product to the immune system as disclosed in copending application 07/800,474, the disclosure of which is incorporated herein by reference.

In general, the dosage range for the prostate antigens of the invention is of the order of 0.01 μg -100 mg per dose, preferably 0.1 μg -10 mg per dose and more preferably 10 μg -1 mg per dose. Suitable volumes for parenteral administration are about 0.1-5 ml.

The protocols may involve administration of cocktails of various antigens or their representatives or may involve sequential administration of these active ingredients. The antigens and their representatives may represent a variety of immunogens or may represent different forms of the same immunogen. In general, protocols involving one or more immunogenic species can be designed according to routine optimization procedures.

The prostatic cancer vaccine of the invention is administered generally in multiple doses, typically once per week for one or two months and with decreasing frequency thereafter for a period extending to about one year. Following the initial one year course of vaccination, booster inoculations may be given every two months to five years. Alternate

protocols may be appropriate in individual instances. For example, if vaccine formulation involves the use of liposomes and is administered intramuscularly, the vaccine might be administered once a month from the inception because of the depot effect of the liposomes.

In addition, it may be advantageous to substitute for the first administrations a recombinant form of the antigen wherein the antigen gene or cDNA is administered in a living expression vector such as vaccinia virus.

It is a further feature of the invention that the vaccine may be formulated along with adjuvants which enhance the immune responses as described above. The prostate antigens may be formulated with these adjuvants alone or they may be incorporated into liposomes.

- 16 -

Claims

1. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises an active ingredient selected from the group consisting of
- 5 at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof with the proviso that said antigen is other than human prostate specific antigen (PSA) produced in human cells;
- 10 an expression system capable of generating *in situ* an antigen over-represented on the prostate gland with respect to other tissues or an immunologically effective portion thereof;
- naked DNA encoding said antigen or portion; and
- an antiidiotypic antibody or fragment thereof which
- 15 mimics said antigen.
2. The vaccine of claim 1 wherein said antigen is selected from the group consisting of PSA, PSMA and PAP.
3. The vaccine of claim 1 or 2 wherein the antigen is encapsulated in a liposome or coupled to a liposome and
- 20 wherein said liposomes optionally contain an adjuvant or are precipitated with alum.
4. The vaccine of any of claims 1-3 which further includes at least one adjuvant capable of enhancing said antitumor immune response.
- 25 5. The vaccine of claim 4 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria polysaccharides; saponins; detoxified endotoxin (DETOX); muramyl tripeptide or
- 30 muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

6. The vaccine of any of claims 1-5 wherein said active ingredient consists essentially of DNA encoding said antigen or portion or wherein said expression system comprises a living expression vector.

5 7. The vaccine of any of claims 1-5 which comprises as active ingredient

at least one antigen over-represented on the prostate gland with respect to other tissues or an immunologically effective portion thereof with the proviso that said antigen is
10 other than human prostate specific antigen (PSA) produced in human cells.

8. A method to induce an antitumor immune response in a potential or actual prostate tumor-bearing subject which method comprises administering to said subject the vaccine of
15 any of claims 1-5.

9. The method of claim 8 wherein said subject is afflicted with metastatic prostate cancer; and/or wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence and wherein said subject is optionally in
20 a "neoadjuvant" setting prior to surgical excision of said prostate tumor; or

wherein said subject is a potential prostate tumor-bearing subject at risk for said tumor.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09045

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 39/395; C07K 14/00; C12N 15/70, 15/79

US CL : 435/320.1; 424/130.1, 131.1, 138.1, 152.1, 184.1; 530/350, 387.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1; 424/130.1, 131.1, 138.1, 152.1, 184.1; 530/350, 387.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, CA, EMBASE, MEDLINE, WPI

search terms: spliter, maida, anti-idiotyp?, prostate tumor?, psa

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,446,122 (CHU ET AL.) 01 MAY 1984, see entire document.	1-9
Y	Cancer Research, Volume 46, issued August 1986, T. Deguchi et al., "Effect of Methotrexate-Monoclonal Anti-Prostatic Acid Phosphatase Antibody Conjugate on Human Prostate Tumor", pages 3751-3755, see entire document.	1-9
Y	J. Immunol. Methods, Volume 140, issued 1991, C.R. Alving, "Liposomes as Carriers of Antigens and Adjuvants", pages 1-13, see entire document.	1-9

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
* A	document defining the general state of the art which is not considered to be of particular relevance		
* E	earlier document published on or after the international filing date	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* O	document referring to an oral disclosure, use, exhibition or other means		
* P	document published prior to the international filing date but later than the priority date claimed	* Z	document member of the same patent family

Date of the actual completion of the international search

06 OCTOBER 1994

Date of mailing of the international search report

07 DEC 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHILLIP GAMBEL

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.

US94/09045

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FASEB J., Volume 2, issued 1988, C.B. Dai et al., "Generation and Characterization of Monoclonal Anti-Idiotypic Antibodies for Dunning Rat Prostate Tumor", page A692, abstract no. 2301, see entire abstract.	1-9

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*